Peptide questions · CJC-1295 no DAC

CJC-1295 no DAC side effects: what studies and users report

Reviewed Evidence: ModeratePublished by PepVault

The side effects most commonly reported for CJC-1295 no DAC are water retention, headache and flushing, among 4 the library lists; its evidence in people comes from small studies without a control group and from clinical use.

Its safety note opens: CJC-1295 without DAC (mod GRF 1-29) is a short-acting GHRH analog with no published human safety study of its own; the phase 1 safety data (relatively well tolerated at 30–60 mcg/kg) are for the long-acting DAC form.

What is commonly reported with CJC-1295 no DAC

  • Water retention
  • Headache
  • Flushing
  • Injection site pain

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other growth hormone compounds the library lists it for
EffectAlso listed for (of 13)
Water retention9: Ipamorelin, CJC-1295 with DAC, Sermorelin, GHRP-2 and 5 more
Headache4: Ipamorelin, CJC-1295 with DAC, Sermorelin, GHRP-2
Flushing3: Ipamorelin, CJC-1295 with DAC, Sermorelin
Injection site pain1: CJC-1295 with DAC
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Track CJC-1295 no DAC in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which CJC-1295 no DAC side effects the growth hormone group shares

Across the 14 growth hormone compounds in the library, the effects listed most often are water retention (10 of 14), headache (5 of 14), injection site reaction (5 of 14) and fatigue (4 of 14). Every effect on CJC-1295 no DAC’s list also appears for at least one other growth hormone compound, so nothing on it is CJC-1295 no DAC’s own.

What the CJC-1295 no DAC safety notes say

The library’s safety note

CJC-1295 without DAC (mod GRF 1-29) is a short-acting GHRH analog with no published human safety study of its own; the phase 1 safety data (relatively well tolerated at 30–60 mcg/kg) are for the long-acting DAC form. FDA says it has identified serious adverse events with CJC-1295, including increased heart rate and systemic vasodilatory reactions, and flags a possible risk of immune reactions. Commonly reported effects are transient water retention, flushing, headache, tingling or numbness in the hands, and possible effects on glucose/insulin sensitivity from GH/IGF-1 elevation; as a short-acting form, these tend to be shorter-lived. Long-term human safety data are lacking. Discuss IGF-1 and glucose monitoring with your clinician.

The library’s interaction note

No formal human interaction studies exist. The key mechanism-based consideration is glucose/insulin sensitivity from sustained GH/IGF-1 elevation — relevant alongside insulin or antidiabetic agents and worth clinician-guided monitoring. Almost always combined with a ghrelin agonist (ipamorelin) for synergistic GH release; this is well-described in practice but lacks formal combination safety trials. No documented interaction with SSRIs, anticoagulants, or thyroid meds; raise all medications with your clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the CJC-1295 no DAC reports come from

The library rates the evidence on CJC-1295 no DAC as moderate: animal studies plus some human data.

Of the library’s 7 research notes on CJC-1295 no DAC, 2 rest on clinical data and 5 on community reports.

So the effects listed for CJC-1295 no DAC come from uncontrolled studies and use in people, not from placebo-controlled trials.

Questions people ask

What are the side effects of CJC-1295 no DAC?

The side effects most commonly reported for CJC-1295 no DAC are water retention, headache and flushing, among 4 the library lists; its evidence in people comes from small studies without a control group and from clinical use.

Do CJC-1295 no DAC’s side effects come from human studies?

The library rates the evidence on CJC-1295 no DAC as moderate, and its evidence in people comes from small studies without a control group and from clinical use.

Which CJC-1295 no DAC side effects are its own?

None: each effect the library lists for CJC-1295 no DAC is listed for at least one other growth hormone compound too.

Does CJC-1295 no DAC interact with other medicines?

The library’s interaction note on CJC-1295 no DAC begins: No formal human interaction studies exist.

More on CJC-1295 no DAC

Track it in the app

PepVault for iPhone

Track CJC-1295 no DAC in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo